Winger EE, Reddy MM, Hargrove D, McHugh T, McKinley GF, Grieco MH; International Conference on AIDS.
Int Conf AIDS. 1991 Jun 16-21; 7: 31 (abstract no. M.B.38).
Immunodiagnostic Laboratories, Inc., San Francisco, California, USA
OBJECTIVE: Current methods for monitoring of HIV viral burden include quantitative PCR, quantitative plasma viral culture and HIV p24 antigen assay. The first two techniques are currently impractical while the latter is relatively insensitive detecting antigen in only a fraction of infected individuals. METHODS: A highly sensitive p24 antigen antigen-capture ELISA assay was developed by Immunodiagnostic Laboratories with sensitivity at one picogram/ml. To further enhance the rate of antigen detection, serum is pretreated with HCl to denature immune complexes and is neutralized prior to analysis. RESULTS: HIV p24 antigen was detected in 50 to 60% of symptomatic patients and 15 to 20% of asymptomatic patients. The highly sensitive assay described was able to detect antigen in greater than 95% of these sera. Patients with ARC and AIDS treated with AZT or ddI who were HIV p24 antigen negative by a commercial antigen-capture ELISA could not be monitored for drug efficacy. All of these cases could be monitored using the sensitive assay technique. CONCLUSIONS: The use of this highly sensitive HIV p24 antigen assay has permitted the monitoring of the efficacy of anti-retroviral therapy.
Publication Types:
Keywords:
- AIDS Vaccines
- AIDS-Related Complex
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antigen-Antibody Complex
- Didanosine
- Enzyme-Linked Immunosorbent Assay
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Infections
- HIV Seropositivity
- Humans
- Viral Load
- Zidovudine
- immunology
- methods
- organization & administration
- therapy
Other ID:
UI: 102181955
From Meeting Abstracts